$HP

Helmerich & Payne (NYSE: HP) insider lines up sale after $1.17M May trade

Helmerich & Payne (NYSE: HP) insider Cara Hair filed a Rule 144 notice to sell 11,149 HP common shares via Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of about $493,581.25. The shares came from restricted stock vesting on Jan. 11, 2022 and Jan. 11, 2024. Hair previously sold 28,345 shares for about $1.17M on May 18, 2026.

Original reporting
Published Aug 17, 2026, 7:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$HP
Neutral
medium confidence
Mentioned
$HP
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HPNeutralLow
01

Why it matters

Traders may monitor for incremental selling around the planned Aug 17, 2026 execution date, but the disclosed planned value is relatively small and lacks a fundamental trigger.

02

Market read

A new Form 144 resale plan adds a modest insider supply signal for HP, with timing tied to Aug 17, 2026.

03

What to watch

The article does not state whether additional insiders plan sales, nor does it provide any change in fundamentals; the prior May sale may already have been absorbed.

Relevance 4/10Novelty 4/10Timing: planned Rule 144 sale date is 08/17/2026

Background

The article summarizes a Rule 144 filing by insider Cara Hair to sell shares of Helmerich & Payne that became eligible after restricted stock vesting in 2022 and 2024.

Company-level read

Ticker impact

$HPNeutralMedium confidence
Context

Helmerich & Payne insider Cara Hair filed a Rule 144 plan to sell 11,149 shares on Aug 17, 2026.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

This is a Form 144 resale plan tied to prior restricted stock vesting, not a new earnings, guidance, or deal catalyst. The planned sale value ($493.6k) is small, so price impact should be muted unless follow-on selling accelerates.

Market effects

No clear sector read-through; this is company-specific insider resale mechanics.

None.

None.

Counterpoint

Rule 144 filings often reflect routine vesting unlocks and planned liquidity, not a bearish view on the stock.

Key entities

  • Helmerich & Payne

    NYSE-listed issuer whose insider resale plan is described.

  • Cara Hair

    Insider who filed to sell HP common stock under Rule 144.

  • Fidelity Brokerage Services LLC

    Brokerage through which the planned sale is to be executed.

Related articles

$HPHighAI 8/10

HP Reports Strong Earnings, Stock Drops 10% Amid Demand Concerns

HP Inc. (NYSE: HP) reported Q3 revenue of $15.7B, up 13% YoY, and adjusted EPS of $0.83, beating expectations. Despite this, shares fell 10% due to concerns over demand and declining PC shipments. HP's P/S ratio is higher than its historical median, suggesting overvaluation. Insiders sold $5.24M in shares recently, indicating mixed sentiment.

$HPMedAI 8/10

Helmerich & Payne Q3 Earnings Call Highlights

Helmerich & Payne (NYSE:HP) reported Q3 call highlights. Management said super-spec fleet utilization is ~95%. For fiscal Q4, North America Solutions guidance is 145-151 rigs with direct margin of $245m-$255m, and full-year North American rig count raised to 140-144. International Solutions direct margin was $31m; Offshore was $29m. Company targets net debt/EBITDA of 1x and raised full-year Offshore direct margin to $113m-$117m.

$HPMed

Helmerich & Payne (NYSE:HP) Reports Upbeat Q2 CY2026

Helmerich & Payne (NYSE:HP) reported Q2 CY2026 results. Revenue was $1.03 billion, flat year on year but 5.4% above Wall Street estimates. GAAP profit was $0.74 per share, above analysts’ consensus. The article also cites adjusted EBITDA margin of 22.8% and notes the stock was about $33.59 after results.

$HPMed

Helmerich & Payne, Inc. (HP): Results of Operations and Financial Condition

Helmerich & Payne, Inc. (HP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE August 5, 2026 HELMERICH & PAYNE, INC. ANNOUNCES FISCAL THIRD QUARTER RESULTS Operating and Financial Highlights for the Quarter Ended June 30, 2026 • H&P announced consolidated revenue of $1.035 billion, reflecting strong sequential growth and solid exe

$HPMedAI 8/10

BofA Raises its Price Target on Helmerich & Payne (HP)

On May 19, 2026, BofA analyst Saurabh Pant raised Helmerich & Payne’s (HP) price target to $44 from $41 and kept a Buy rating, citing updated oilfield services models after Q1 earnings and 10-Q filings. BofA said 2027 and 2028 EBITDA forecasts are about 10% and 16% above consensus. Piper Sandler raised its target to $43 from $41 with an Overweight rating.